NTRK2 and major depressive disorder: Finally, the use of novel biomarkers (e.g., blood levels of proBDNF or BDNF) for MDD could prove invaluable in detecting the antidepressant efficacy of TrkB agonists/antagonists (Hashimoto, 2010, 2014a, 2014b).